South Park Took On Crypto, AI Previously: Animated Comedy Targets Weight-Loss Drug Ozempic Next
- "South Park: The End of Obesity" Special: Premieres on May 24 in the U.S. and Canada, tackling weight-loss drugs in a comedic manner.
- Content of the Special: The fictional town of South Park becomes obsessed with weight loss drugs, with main character Cartman using them to get skinny.
- Previous Streaming Specials: "South Park" has addressed various topics like COVID-19, streaming, and artificial intelligence in previous streaming exclusives.
- Impact of the Parody: The special could portray weight-loss drugs negatively, similar to how the series covered cryptocurrency and AI in the past.
- Market Impact: Weight loss drugs like Wegovy and Ozempic have seen stock gains; Roundhill Investments launched an ETF focused on stocks related to weight loss drugs.
Trade with 70% Backtested Accuracy
Analyst Views on OZEM
About the author
Last Week's Six Best-Performing ETF Sectors
Market Performance: Last week, the S&P 500 fell by 0.6%, while the Dow Jones rose by 1.1% and the Nasdaq dropped by 1.6%, primarily due to declines in tech stocks, including a 14% drop in Oracle's shares.
Federal Reserve Actions: The Fed implemented its final rate cut of the year, lowering the benchmark federal funds rate to 3.5%-3.75%, with projections indicating a more restrained outlook for 2026.
ETF Highlights: Notable ETF performances included significant gains in the cannabis sector, with the Roundhill Cannabis ETF up 51.2%, and strong performances in silver miners and the space economy, driven by rising demand and investor interest.
Emerging Trends: The Roundhill GLP-1 & Weight Loss ETF gained 6.3%, reflecting optimism in weight loss drugs as a major advancement in pharmaceuticals, while platinum prices surged due to anticipated market deficits.
Top-Performing ETFs for November
Market Performance: Wall Street experienced a mixed November, with the S&P 500 down 0.04%, the Dow Jones up 0.8%, and the Nasdaq down 0.9%, influenced by reduced expectations for Fed rate cuts and concerns over an AI bubble.
Healthcare Sector Growth: The healthcare sector thrived, with the Health Care Select Sector SPDR Fund gaining about 9.1%, driven by investor interest in non-cyclical sectors, highlighted by Eli Lilly briefly reaching a $1 trillion market cap.
NVIDIA's Earnings and SoftBank's Stake Sale: NVIDIA reported strong earnings, but its shares fell 14.4% amid AI spending concerns, while SoftBank sold its entire stake in NVIDIA for $5.83 billion to fund investments in OpenAI.
Natural Gas Price Surge: Natural gas prices rose due to forecasts of a colder winter in the U.S. and other regions, with the United States Natural Gas Fund surging about 7% over the month.
Novo Nordisk's Stock Decline Highlights the Side Effect of GLP-1 Investments: ETF Concentration Risk
Novo Nordisk's Market Impact: Novo Nordisk experienced a significant drop in stock price following disappointing results from its Alzheimer’s trials, raising concerns about the volatility of healthcare ETFs heavily reliant on a few key players like Novo and Eli Lilly.
Concentration Risk in ETFs: ETFs such as the Roundhill GLP-1 & Weight Loss ETF and the VanEck Pharmaceutical ETF are heavily weighted towards Eli Lilly and Novo Nordisk, making them vulnerable to fluctuations in these companies' performances.
Eli Lilly's Resilience: Despite the challenges faced by Novo, Eli Lilly's diverse portfolio and strong revenue from multiple products position it favorably, suggesting that Lilly-heavy ETFs may remain stable even amid short-term setbacks in the GLP-1 market.
Investor Considerations: The recent developments highlight the importance for investors in healthcare ETFs to assess their exposure to Novo Nordisk's risks versus Eli Lilly's resilience, as the GLP-1 boom continues to reshape the sector.
Eli Lilly Strengthens Position in $150B Obesity Drug Competition Amid Novo and Pfizer Rivalry — Potential Benefits for ETFs
Healthcare ETFs Capitalizing on Obesity Drug Boom: Healthcare ETFs are benefiting from the $150 billion obesity-drug market, with major players like Eli Lilly, Novo Nordisk, and Pfizer competing for market share, leading to increased investor interest in diversified ETFs.
Eli Lilly's Strong Performance: Eli Lilly's stock rose nearly 5% following impressive third-quarter earnings, prompting a raised profit forecast, while its significant presence in major healthcare ETFs like XLV and IHE highlights its dominance in the sector.
Novo Nordisk's Strategic Moves: Novo Nordisk is making headlines with a $6.5 billion counterbid for biotech Metsera, which is developing innovative weight-loss treatments, intensifying competition in the GLP-1 market against Pfizer's earlier bid.
Emergence of Themed ETFs: The Roundhill GLP-1 & Weight Loss ETF offers a focused investment opportunity in companies leading the anti-obesity trend, reflecting the growing interest in specialized funds within the pharmaceutical landscape.
NVO Receives FDA Approval for MASH Therapy: ETFs Expected to Benefit
Wegovy Approval: Novo Nordisk's obesity drug, Wegovy, received accelerated FDA approval to treat metabolic dysfunction-associated steatohepatitis (MASH), marking it as the first GLP-1 class treatment for this liver condition.
Efficacy Results: The approval is based on the ESSENCE trial results, showing that 62.9% of participants on Wegovy achieved resolution of steatohepatitis without worsening fibrosis, compared to 34.3% on placebo.
Market Impact: Following the announcement, Novo Nordisk's shares rose nearly 4%, and Wegovy is expected to significantly contribute to the company's revenue from MASH treatments.
ETF Exposure: Several exchange-traded funds (ETFs) have substantial holdings in Novo Nordisk, including Roundhill GLP-1 & Weight Loss ETF, Amplify Weight Loss Drug & Treatment ETF, and VanEck Pharmaceutical ETF.
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data
Eli Lilly's Q2 Performance: Eli Lilly reported strong second-quarter results for 2025, exceeding earnings and revenue estimates due to high demand for its diabetes and weight-loss drugs, leading to an increased full-year outlook. However, shares fell 14% following disappointing data on a new weight-loss pill, orforglipron.
ETF Investment Opportunities: Investors looking to capitalize on Eli Lilly's performance can consider various ETFs with significant exposure to the company, including iShares U.S. Pharmaceuticals ETF, VanEck Vectors Pharmaceutical ETF, and Roundhill GLP-1 & Weight Loss ETF, among others.
Last Week's Six Best-Performing ETF Sectors
Market Performance: Last week, the S&P 500 fell by 0.6%, while the Dow Jones rose by 1.1% and the Nasdaq dropped by 1.6%, primarily due to declines in tech stocks, including a 14% drop in Oracle's shares.
Federal Reserve Actions: The Fed implemented its final rate cut of the year, lowering the benchmark federal funds rate to 3.5%-3.75%, with projections indicating a more restrained outlook for 2026.
ETF Highlights: Notable ETF performances included significant gains in the cannabis sector, with the Roundhill Cannabis ETF up 51.2%, and strong performances in silver miners and the space economy, driven by rising demand and investor interest.
Emerging Trends: The Roundhill GLP-1 & Weight Loss ETF gained 6.3%, reflecting optimism in weight loss drugs as a major advancement in pharmaceuticals, while platinum prices surged due to anticipated market deficits.
Top-Performing ETFs for November
Market Performance: Wall Street experienced a mixed November, with the S&P 500 down 0.04%, the Dow Jones up 0.8%, and the Nasdaq down 0.9%, influenced by reduced expectations for Fed rate cuts and concerns over an AI bubble.
Healthcare Sector Growth: The healthcare sector thrived, with the Health Care Select Sector SPDR Fund gaining about 9.1%, driven by investor interest in non-cyclical sectors, highlighted by Eli Lilly briefly reaching a $1 trillion market cap.
NVIDIA's Earnings and SoftBank's Stake Sale: NVIDIA reported strong earnings, but its shares fell 14.4% amid AI spending concerns, while SoftBank sold its entire stake in NVIDIA for $5.83 billion to fund investments in OpenAI.
Natural Gas Price Surge: Natural gas prices rose due to forecasts of a colder winter in the U.S. and other regions, with the United States Natural Gas Fund surging about 7% over the month.
Novo Nordisk's Stock Decline Highlights the Side Effect of GLP-1 Investments: ETF Concentration Risk
Novo Nordisk's Market Impact: Novo Nordisk experienced a significant drop in stock price following disappointing results from its Alzheimer’s trials, raising concerns about the volatility of healthcare ETFs heavily reliant on a few key players like Novo and Eli Lilly.
Concentration Risk in ETFs: ETFs such as the Roundhill GLP-1 & Weight Loss ETF and the VanEck Pharmaceutical ETF are heavily weighted towards Eli Lilly and Novo Nordisk, making them vulnerable to fluctuations in these companies' performances.
Eli Lilly's Resilience: Despite the challenges faced by Novo, Eli Lilly's diverse portfolio and strong revenue from multiple products position it favorably, suggesting that Lilly-heavy ETFs may remain stable even amid short-term setbacks in the GLP-1 market.
Investor Considerations: The recent developments highlight the importance for investors in healthcare ETFs to assess their exposure to Novo Nordisk's risks versus Eli Lilly's resilience, as the GLP-1 boom continues to reshape the sector.
Eli Lilly Strengthens Position in $150B Obesity Drug Competition Amid Novo and Pfizer Rivalry — Potential Benefits for ETFs
Healthcare ETFs Capitalizing on Obesity Drug Boom: Healthcare ETFs are benefiting from the $150 billion obesity-drug market, with major players like Eli Lilly, Novo Nordisk, and Pfizer competing for market share, leading to increased investor interest in diversified ETFs.
Eli Lilly's Strong Performance: Eli Lilly's stock rose nearly 5% following impressive third-quarter earnings, prompting a raised profit forecast, while its significant presence in major healthcare ETFs like XLV and IHE highlights its dominance in the sector.
Novo Nordisk's Strategic Moves: Novo Nordisk is making headlines with a $6.5 billion counterbid for biotech Metsera, which is developing innovative weight-loss treatments, intensifying competition in the GLP-1 market against Pfizer's earlier bid.
Emergence of Themed ETFs: The Roundhill GLP-1 & Weight Loss ETF offers a focused investment opportunity in companies leading the anti-obesity trend, reflecting the growing interest in specialized funds within the pharmaceutical landscape.
NVO Receives FDA Approval for MASH Therapy: ETFs Expected to Benefit
Wegovy Approval: Novo Nordisk's obesity drug, Wegovy, received accelerated FDA approval to treat metabolic dysfunction-associated steatohepatitis (MASH), marking it as the first GLP-1 class treatment for this liver condition.
Efficacy Results: The approval is based on the ESSENCE trial results, showing that 62.9% of participants on Wegovy achieved resolution of steatohepatitis without worsening fibrosis, compared to 34.3% on placebo.
Market Impact: Following the announcement, Novo Nordisk's shares rose nearly 4%, and Wegovy is expected to significantly contribute to the company's revenue from MASH treatments.
ETF Exposure: Several exchange-traded funds (ETFs) have substantial holdings in Novo Nordisk, including Roundhill GLP-1 & Weight Loss ETF, Amplify Weight Loss Drug & Treatment ETF, and VanEck Pharmaceutical ETF.
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data
Eli Lilly's Q2 Performance: Eli Lilly reported strong second-quarter results for 2025, exceeding earnings and revenue estimates due to high demand for its diabetes and weight-loss drugs, leading to an increased full-year outlook. However, shares fell 14% following disappointing data on a new weight-loss pill, orforglipron.
ETF Investment Opportunities: Investors looking to capitalize on Eli Lilly's performance can consider various ETFs with significant exposure to the company, including iShares U.S. Pharmaceuticals ETF, VanEck Vectors Pharmaceutical ETF, and Roundhill GLP-1 & Weight Loss ETF, among others.
